论文部分内容阅读
日前,恒瑞医药(600276)与澳大利亚维奥生物科技集团公司正式签约,以开发治疗肿瘤用药送药系统,所谓的送药系统即通过口服、输液、创贴和喷射等技术性手段将药物的有效成分迅速、准确地送达病灶或病源位置,并产生相应作用。近年来随着生物医药技术的发展,新型的生物送药系统已具有指向性,在降低用药量的同时,加大药效,降低副作用。二者联合开发恒瑞肿瘤用药送药系统,借助该系统,恒瑞医药将开发出副作用更小、疗效更显著、费用更低廉的抗肿瘤药物。恒瑞与维奥集团的合作,将为恒瑞医药开发出更先进
A few days ago, Hengrui Pharmaceutical (600276) and Australia’s Vio Biotechnology Group Co., Ltd. formally signed a contract to develop a drug delivery system for the treatment of oncology drugs. The so-called drug delivery system is effective through oral, infusion, patch and injection techniques. The ingredients are quickly and accurately delivered to the location of the lesion or source and have a corresponding effect. In recent years, with the development of biomedical technology, the new type of bio-delivery system has been directed to reduce drug use, increase efficacy, and reduce side effects. The two jointly developed Hengrui’s drug delivery system for oncology. With the help of this system, Hengrui Pharmaceutical will develop antitumor drugs with fewer side effects, more significant effects, and lower costs. The cooperation between Hengrui Group and Vioxx Group will develop more advanced technology for Hengrui Pharmaceuticals